Cardio3 BioSciences Ups R&D Efforts After CV Stem Cell Product Clears Safety Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian regenerative therapies company plans to enlarge its R&D and partnering efforts after a pre-planned interim review by a Data Safety Monitoring Board gave the Phase III study of lead product C-Cure a clean bill of health.